Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 17/20 | 0.71 |
| ▸ | SELP | P16109 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257570 | 0.96 | SELE (0.69) | SELESELP | |
| SCHEMBL13657266 | 0.96 | SELE (0.65) | SELESELP | |
| SCHEMBL15214014 | 0.95 | SELE (0.65) | SELESELP | |
| SCHEMBL13312082 | 0.93 | SELE (0.62) | SELESELP | |
| SCHEMBL15488911 | 0.92 | SELE (0.62) | SELESELP | |
| SCHEMBL13295107 | 0.92 | SELE (0.61) | SELESELP | |
| SCHEMBL14558013 | 0.92 | SELE (0.61) | SELESELP | |
| SCHEMBL15434745 | 0.92 | SELE (0.59) | SELESELP | |
| SCHEMBL16257616 | 0.90 | SELE (0.58) | SELESELP | |
| SCHEMBL16257568 | 0.89 | SELE (0.60) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS INC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8895510-B2 | Pan-selectin inhibitor with enhanced pharmacokinetic activity | GLYCOMIMETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GLYCOMIMETICS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-8518896-B2 | Treatment of cancers of the blood using selected glycomimetic compounds | GLYCOMIMETICS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2318015-B1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | GLYCOMIMETICS INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8410066-B2 | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors | GLYCOMIMETICS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885 |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | SELPLG, SELP, SELE | SELE 3/4885SELP 2/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885 |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GAP43, PYGB, NLN | SELE 1302/4885SELP 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.